Biotech companies occupy an extraordinary position. Their products have the potential to be the 'super' drugs of the future but by their very nature, the potential uses are limited by their specificity. Almost inevitably, the cost of running large-scale trials required by the regulators means that continuing investment is essential. This, in turn means that time and effort needs to be spent in developing materials to show potential investors in order to convince them of the value of the products.

We have helped a number of companies to do just this.

through our contacts with several VC companies, we may be able to help you source new funding